Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

55.26 -1.36 (-2.40%)
Official Closing Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
News headline image
ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades' ↗
Malcolm Ethridge from Capital Area Planning Group sees potential in ServiceNow, Inc. despite recent dip. Bristol-Myers and Live Nation also highlighted. 
Via Benzinga
News headline image
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Identified as a Top Value Stock with Strong Fundamentals ↗
Bristol-Myers Squibb (BMY) is a top value stock with a low P/E ratio of 7.2, strong profitability, and a high 5.19% dividend yield. 
Via Chartmill
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About Bristol-Myers Squibb? ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: Bristol-Myers Squibb ↗
 
Via Benzinga
News headline image
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday? ↗
A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp. 
Via Benzinga
Topics Economy
News headline image
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS ↗
Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks ↗
The dividend stocks listed below all yield more than 5% and look like safe long-term buys. 
Via The Motley Fool
News headline image
BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue... 
Via StockStory
News headline image
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts ↗
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
News headline image
PRME Revenue Misses by 73% ↗
Via The Motley Fool
News headline image
Is It Time to Buy Biotech Stocks? ↗
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
News headline image
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program ↗
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
News headline image
1 Small-Cap Biotech Stock Poised for a Breakout ↗
This developmental biotech is nearing a key inflection point. 
Via The Motley Fool
Topics Economy
News headline image
Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
From Bristol Myers Squibb
Via Business Wire
News headline image
Why Is Replimune Stock Trading Lower On Monday? ↗
Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE trial. 
Via Benzinga
News headline image
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth ↗
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance. 
Via Benzinga
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via Investor Brand Network
Topics Government
News headline image
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
News headline image
This Biotech Stock Could Soar on Upcoming Clinical Data ↗
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
News headline image
Bristol Myers (BMY) Q2 EPS Jumps 36% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' ↗
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
News headline image
Bristol-Myers Squibb Unusual Options Activity For July 31 ↗
 
Via Benzinga
News headline image
Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results... 
Via StockStory
Topics Intellectual Property World Trade
News headline image
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue... 
Via StockStory
News headline image
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion ↗
Bristol Myers beat Q2 sales expectations but cut its 2025 EPS forecast as strategic charges and legacy product declines weighed on earnings. 
Via Benzinga
News headline image
Bristol-Myers Squibb Co (NYSE:BMY) Surpasses Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading ↗
Bristol-Myers Squibb (BMY) beats Q2 2025 revenue and EPS estimates, driving a 2.9% pre-market stock surge. Strong oncology, immunology, and cardiovascular drug sales fuel growth. 
Via Chartmill
News headline image
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A High-Yield Dividend Stock with Strong Profitability and Financial Health ↗
Bristol-Myers Squibb (BMY) offers a high 5.06% dividend yield, strong profitability, and solid financial health, making it a top pick for income investors. Its undervalued stock and consistent payout... 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.